- Global Pharma News & Resources

Follow-on Biologics Market Worth Around 39 Billion USD by 2025 | Whopping CAGR 24.1%

According to Ameco Research, the Global Follow-on Biologics Market is projected to grow at whopping CAGR of around 24.1% over the forecast period and market size will reach worth around 39 Billion US$ in 2019-2025.

The latest trending report Global Follow-on Biologics Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 offered by Ameco Research is an informative study covering the market with detailed analysis. The report will assist reader with better understanding and decision making.

The Global Follow-on Biologics Market is an in depth study analyzing the current state and forecast 2019-2025. It provides brief overview of the market focusing on definitions, market segmentation, end-use applications and industry chain analysis. The study on Global Follow-on Biologics Market provides analysis of market covering the industry trends, recent developments in the market and competitive landscape. Competitive analysis includes competitive information of leading players in market, their company profiles, product portfolio, capacity, production, and company financials.

Download Sample Copy Of This Report From Here:

In addition, report also provides upstream raw material analysis and downstream demand analysis along with the key development trends and sales channel analysis. Research study on Global Follow-on Biologics Market discusses the opportunity areas for investors.

The report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Follow-on Biologics.

This report studies the global market size of Follow-on Biologics, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Follow-on Biologics sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
Teva Pahrmaceutical
Samsung Biologics
Dr. Reddy's Laboratories
Stada Arzneimittel AG

Market Segment by Product Type
Recombinant Non-glycosylated Proteins
Recombinant Glycosylated Proteins
Recombinant Peptides

Market Segment by Application
Blood Disorders
Chronic Diseases
Autoimmune Diseases
Growth Hormone Deficiency
Infectious Diseases
Other Diseases

Key Regions split in this report: breakdown data for each region.
United States
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

Few Significant Points From Table Of Contents:

Global Follow-on Biologics Market - Industry Size, Share, Trends and Forecast 2019 - 2025

1 Report Overview
2 Global Growth Trends
3 Market Share by Manufacturers
4 Market Size by Type
5 Market Size by Application
6 United States
7 European Union
8 China
9 Rest of World
10 Company Profiles
11 Value Chain and Sales Channels Analysis
12 Market Forecast
13 Research Findings and Conclusion
14 Appendix

Quick Buy This Premium Report From Here:


Email: | +1 407 915 4157

For More Latest Pharma amp; Healthcare Updates @ Pharma and Healthcare


Recently Published Reports: Global Biosimilar Monoclonal Antibodies Market Insights, Size, Share, Trend and Forecast 2018-2025

Global Biosimilar Monoclonal Antibodies Market research report 2018 and forecast to 2025 providing a complete analysis of the market size, share, growth, trend, demand, outlook, classification revenue details, competitive scenario, industry analysis, markets forecast, CAGR, product and application.

Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.

The classification of Biosimilar Monoclonal Antibodies includes Infliximab, Rituximab, Trastuzumab, Adalimumab and Other, and the sales proportion of Infliximab in 2017 is about 36.5%.

Biosimilar Monoclonal Antibodies is widely used for Oncology, Autoimmune Disease and Others. The most proportion of Biosimilar Monoclonal Antibodies is sales in Autoimmune Disease, and the consumption proportion is about 85.6% in 2017.


Editor Details

Last Updated: 10-Jun-2019